7 research outputs found

    Psychoemotional state and bioelectrical brain activity in patients of different ages with metabolic syndrome after COVID-19

    Get PDF
    The aim of this study was to find out the impact of COVID-19 infection on the psycho-emotional state and bioelectrical brain activity in persons of different ages with metabolic syndrome. Material and methods. We examined 53 people who were divided into groups depending on age (40–59 years and 60 years and older) and status with regard to COVID-19 infection (contracted, not contracted). Patients had metabolic syndrome (ATP III), underwent comprehensive clinical and laboratory examinations, electroencephalography (an 18-channel electroencephalograph Nihon Kohden, Japan) and answered the Hospital Anxiety and Depression Scale (HADS) questionnaire. Results. Symptoms of anxiety or depression after COVID-19 were found in both age groups of MS. Anxiety symptoms were more often found in the group of 60 years and older. At the same time, subclinical anxiety was noted in persons of 60 years and older, while clinical anxiety – in middle-aged individuals. The latter also showed a trend towards an increase in clinically evident depression after COVID-19. Persons after COVID-19 with symptoms of anxiety or depression (according to the HADS scale) demonstrated changes in the frequency-amplitude indicators of the electroencephalogram (EEG) characterized by a power increase in the range of theta rhythm and accompanied by subclinical and clinical manifestations of depression. About 80 % of people who did not suffer from COVID-19 had normal EEG since 9 Hz alpha rhythm power was registered. In patients after COVID-19, there was a redistribution of alpha-rhythm power range: an increase in the ranges of alpha-1 rhythm and decrease in alpha-2 rhythm power as well as an increase in the delta and theta rhythm power range. Conclusions. 1–3 months following the acute period of COVID-19, the frequency of depression is 3 times higher in middle-aged patients with metabolic syndrome. In elderly patients with metabolic syndrome after COVID-19, anxiety is predominantly diagnosed – almost in every second. These manifestations of anxiety and depression are accompanied by disorganization of the bioelectrical brain activity

    Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

    Get PDF
    BACKGROUND Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. METHODS We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. RESULTS A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001); the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74; 95% CI, 0.65 to 0.83; P<0.001). The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. 2.1%, P=0.004). Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06). CONCLUSIONS Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361

    Система управління сестринським персоналом у закладах охорони здоров’я україни

    No full text
    The management in nursing is analysed in the article. An attempt has been made to improve the training system of nurses of bachelor and master degrees and position them in the career structuring vertical of the healthcare environment, with changes of tasks and functions that must be supported by the regulatory and legal framework.В статье проанализировано состояние менеджмента в медсетринстве. Сделана попытка усовершенствовать систему подготовки медицинских сестер уровня бакалавра и магистра и найти им место в структурной вертикали медицинской отрасли, с изменением задач и функций, которые должны быть закреплены нормативно-правовой базой.У статті проаналізовано стан менеджменту у медсестринстві. Зроблена спроба удосконалити систему підготовки медичних сестер за рівнем бакалавр та магістр і знайти їм місце у структурній вертикалі медичної галузі, зі зміною завдань та функцій, які мають бути підкріплені нормативно-правовою базою

    Communicative Socialization of Students

    No full text
    У розділі досліджуються особливості комунікативної соціалізації студентів в сучасних умовах. The features of communicative socialization of students in nowadays settings are explored in the chapter

    Evolocumab and clinical outcomes in patients with cardiovascular disease

    Full text link
    peer reviewedBACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. METHODS We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy. Patients were randomly assigned to receive evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The median duration of follow-up was 2.2 years. RESULTS At 48 weeks, the least-squares mean percentage reduction in LDL cholesterol levels with evolocumab, as compared with placebo, was 59%, from a median baseline value of 92 mg per deciliter (2.4 mmol per liter) to 30 mg per deciliter (0.78 mmol per liter) (P<0.001). Relative to placebo, evolocumab treatment significantly reduced the risk of the primary end point (1344 patients [9.8%] vs. 1563 patients [11.3%]; hazard ratio, 0.85; 95% confidence interval [CI], 0.79 to 0.92; P<0.001) and the key secondary end point (816 [5.9%] vs. 1013 [7.4%]; hazard ratio, 0.80; 95% CI, 0.73 to 0.88; P<0.001). The results were consistent across key subgroups, including the subgroup of patients in the lowest quartile for baseline LDL cholesterol levels (median, 74 mg per deciliter [1.9 mmol per liter]). There was no significant difference between the study groups with regard to adverse events (including new-onset diabetes and neurocognitive events), with the exception of injection-site reactions, which were more common with evolocumab (2.1% vs. 1.6%). CONCLUSIONS In our trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events. These findings show that patients with atherosclerotic cardiovascular disease benefit from lowering of LDL cholesterol levels below current targets. © 2017 Massachusetts Medical Society

    Evolocumab and clinical outcomes in patients with cardiovascular disease

    No full text
    BACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. METHODS We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy. Patients were randomly assigned to receive evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The median duration of follow-up was 2.2 years. RESULTS At 48 weeks, the least-squares mean percentage reduction in LDL cholesterol levels with evolocumab, as compared with placebo, was 59%, from a median baseline value of 92 mg per deciliter (2.4 mmol per liter) to 30 mg per deciliter (0.78 mmol per liter) (P<0.001). Relative to placebo, evolocumab treatment significantly reduced the risk of the primary end point (1344 patients [9.8%] vs. 1563 patients [11.3%]; hazard ratio, 0.85; 95% confidence interval [CI], 0.79 to 0.92; P<0.001) and the key secondary end point (816 [5.9%] vs. 1013 [7.4%]; hazard ratio, 0.80; 95% CI, 0.73 to 0.88; P<0.001). The results were consistent across key subgroups, including the subgroup of patients in the lowest quartile for baseline LDL cholesterol levels (median, 74 mg per deciliter [1.9 mmol per liter]). There was no significant difference between the study groups with regard to adverse events (including new-onset diabetes and neurocognitive events), with the exception of injection-site reactions, which were more common with evolocumab (2.1% vs. 1.6%). CONCLUSIONS In our trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events. These findings show that patients with atherosclerotic cardiovascular disease benefit from lowering of LDL cholesterol levels below current targets
    corecore